62
Participants
Start Date
January 10, 2020
Primary Completion Date
March 22, 2024
Study Completion Date
November 19, 2024
Sorafenib+YIV-906
Patients will be given sorafenib (400 mg BID) daily for a 28-day course with YIV-906 (3 capsules, BID) 4 days on and 3 days off weekly in each course.
Sorafenib+placebo
Patients will be given sorafenib (400 mg BID) daily for a 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
Memorial Sloan Kettering Cancer Center, New York
Northwell Monter Cancer Institute, Lake Success
Calvin Pan. MD Gastroenterology & Hepatology Clinic, Flushing
University Hospitals Cleveland Medical Center, Cleveland
Beijing You'An Hospital, Capital Medical University, Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
China-Japan Friendship Hospital, Beijing
Foshan Hospital of Traditional Chinese Medicine, Foshan
Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou
Shenzhen People's Hospital, Shenzhen
The First Affiliated Hospital of Guangxi Medical University, Nanning
Hunan Cancer Hospital, Changsha
LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai
Shanghai Eastern Hepatobiliary Hospital, Shanghai
Shanghai University of Traditional Chinese Medicine Shuguang Hospital, Shanghai
Queen Mary Hospital, Hong Kong
China Medical University Hospital, Taichung
National Cheng Kung University Hospital, Tainan City
Cancer Research Center, Taipei Municipal Wanfang Hospital, Taipei
Taipei Medical University -Shuang Ho Hospital, Ministry of Health and Welfare, Taipei
Taipei Medical University Cancer Center, Taipei
Taipei Veterans General Hospital, Taipei
Chang Gung Memorial Hospital, Linkou, Taoyuan District
Yiviva Inc.
INDUSTRY